Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

Items 11-19 of 19

Page
per page
  1. PD173955
    A8812 PD173955
    Target: Bcr-Abl|Src
    Summary: Dual Src/Abl kinase inhibitor, ATP-competitive,
      ≥22.15 mg/mL
  2. GZD824
    B1402 GZD824
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor,novel orally bioavailable
      ≥36.25 mg/mL
  3. Bafetinib (INNO-406)
    B1011 Bafetinib (INNO-406)
     2 Citation
    Summary: Bcr-Abl/Lyn tyrosine kinase inhibitor
      ≥57.7 mg/mL
  4. DCC-2036 (Rebastinib)
    B1404 DCC-2036 (Rebastinib)
    Target: FLT3|Bcr-Abl|Tie-2|KDR
    Summary: Bcr-Abl inhibitor
      ≥27.7 mg/mL
  5. AG957
    C5826 AG957
    Summary: a tyrphostin that targets transforming Bcr-Abl fusion proteins
  6. GNF-7
    B6033 GNF-7
    Summary: Type II Bcr-Abl inhibitor
      insoluble in EtOH; insoluble in H2O; ≥5.48 mg/mL
  7. PD 166326
    C3677 PD 166326
    Summary: receptor tyrosine kinases inhibitor
      ≤25 mg/mL
  8. Dasatinib (BMS-354825)
    A3017 Dasatinib (BMS-354825)
     4 Citation
    Summary: Src and BCR-Abl inhibitor
      ≥24.4 mg/mL
  9. Nilotinib monohydrochloride monohydrate
    A3660 Nilotinib monohydrochloride monohydrate
    Summary: Bcr-Abl inhibitor
      ≥50 mg/mL

Items 11-19 of 19

Page
per page